权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Protection Against Nosocomial Infections After Severe Burn Injury Through Trained Immunity

通过训练有素的免疫力预防严重烧伤后的医院感染

基本信息

批准号：
10592960
负责人：
Julia K. Bohannon
金额：
$ 1.79万
依托单位：
VANDERBILT UNIVERSITY MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-05-01 至 2026-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10592960
关键词：
Agonist Burn injury Cause of Death Cells Drug Targeting Exposure to Functional disorder Genetic Goals High Prevalence Hospitalization Human Immune Immune System Diseases Immune response Immune system Immunity Immunologic Memory Immunotherapeutic agent Immunotherapy Infection Infection prevention Knowledge Leukocytes Life Mediating Metabolic Mitochondria Modification Molecular Mus Myeloid Cells Nosocomial Infections Oxidative Stress Patients Research Resistance Resistance to infection Signal Pathway Signal Transduction Stimulus TLR4 gene Techniques Therapeutic Tissue-Specific Gene Expression Toll-like receptors Training antimicrobial burn model clinical application clinical development clinical efficacy clinically relevant drug resistant pathogen immunomodulatory therapies immunoregulation improved macrophage pathogen programs response severe burns therapeutic target

项目摘要

PROJECT SUMMARY Nosocomial infections remain the leading cause of death in severely burned patients due to barrier loss, im- paired immunity, and high prevalence of antibiotic resistant pathogens. Immunomodulatory strategies aimed at augmenting the host response are greatly needed. Evidence suggests that Toll-like receptor (TLR) agonists hold strong promise as immunotherapeutic agents to achieve that goal. Priming with TLR4 agonists enhances resistance against a variety of clinically relevant infections associated with severe burn injury in mice via induc- tion of “trained immunity” whereby innate immune cells become more responsive to subsequent infectious stimuli. TLR4-mediated trained immunity is characterized by metabolic reprogramming and mitochondrial ex- pansion in macrophages which boost antimicrobial responses. Cellular signaling mechanisms responsible for TLR-mediated trained immunity and the effect of burn injury on metabolic and mitochondrial function in innate leukocytes remains to be elucidated. Our research program aims to investigate immunomodulatory therapies for prevention of infection following severe burn by elucidating burn-induced immunometabolic dysfunction and the potential for triggering trained immunity for protection after burn. To achieve these goals, we will pursue three integrated projects: Project 1 will investigate the impact of severe burn and post-burn infection on myeloid cell immunometabolism and mitochondrial function. We will assess metabolic, mitochondrial, and antimicrobial function using a variety of techniques including glycolytic and oxidative stress capacity, mitochon- drial content and function analyses, and differential gene expression in mouse and human leukocytes after burn. This project will expand our understanding of molecular mechanisms behind burn-induced leukocyte dys- function. Project 2 will evaluate mechanisms by which TLR agonists induce trained immunity in leuko- cytes after burn. We will use genetic modification, TLR signaling pathway-selective agonism, and signaling pathway blockade to investigate the molecular mechanisms involved in TLR-mediated induction of trained im- munity after burn. We will examine the ability of TLR agonists to induce trained immunity in leukocytes from burn patients. This project will fill critical gaps in our understanding of mechanisms by which we can improve resistance to infections in burn patients. Project 3 will elucidate the potential of targeting TLR-signaling pathways for therapeutic benefit in clinically relevant models of burn-associated infection. We will de- termine the efficacy of clinically applicable TLR agonists in conferring protection against a variety of pathogens prevalent in burn patients. We will evaluate protection duration, extension of protection upon repeated therapy, and whether TLR agonists can promote infection clearance after infection onset. This project will reveal poten- tial drug targets that should be considered for clinical development for mediating protection against nosocomial infections in burn patients. These projects will enhance our understanding of burn-induced innate immune dys- function and identify therapeutic targets to improve immunity and protect against burn-related infections.

项目总结